General Information

G34R/V mutated gliomas are considered a rare disease and are often diagnosed in the young adult/adolescent population. Despite improvements in the diagnostic landscape of these aggressive high grade gliomas, the therapeutic advancements have lagged, leaving clinicians to struggle with optimal treatment options.

During this conference, we will review published and ongoing research centered on G34R/V mutated glioma discoveries to date and discuss via small groups and larger forums on how best to advance research as well as treat these complex patients.

This comprehensive day-long conference is designed for neurooncologists, neurooncology researchers, tumor biologists, oncologists, neurologists, neurosurgeons, neuropathologists, advanced practice nurses, nurses, physician assistants, fellows, students, and other allied health professionals involved with or interested in the treatment of patients with malignant brain tumors.


NINDS_G34RV_poster final.pdf

svg Meeting Contacts

svg Sponsored By

  • National Institutes of Neurological Disorders and Stroke (NINDS)
  • National Cancer Institute (NCI)
  • National Center for Advanced Sciences and Technology (NCATS)
  • Foundation for Advanced Education in the Sciences (FAES)

Sessions/Agenda

What about G34R/V Mutated Gliomas?: Challenges and Opportunities - In-Person Session
Friday, May 31, 2024
07:30 AM-05:00 PM(EST)
Rockledge II
6701 Rockledge Drive,
Bethesda, MD - 20817
Max.Capacity: 75 Participants: 47

Logistics

Visitor Information

Symposium Location

This meeting will take place at Rockledge II, 6701 Rocklege Drive, Bethesda, MD 20817. While very close, none of the sessions will take place on the NIH main Bethesda campus.  

Meals 

Morning and afternoon meals will all be provided on site. Warm breakfast with coffee/tea will be served (courtesy of NIH FAES). A delicious warm lunch with beverage selections will be provided (courtesy of Chimerix).  

Lodging 

Shuttle service will provide transportation from Embassy Suites by Hilton Bethesda, starting at 7:15am and provide return trips to the hotel at approximately 5:15pm. 

Driving Directions

From I-495 (Capital Beltway) in Northern Virginia:
Take I-495 (Capital Beltway) northbound (Inner Loop).
Stay to the left and enter I-270 North at the I-270 spur.
Take Exit 1 to Democracy Boulevard.
At the third traffic light, turn left onto Fernwood Drive.
At the third traffic light, turn right onto Rockledge Drive.
Follow Rockledge Drive about 1/2 mile.
Rockledge I & II are located on your left.


From I-495 (Capital Beltway) in Maryland:
Take I-495 (Capital Beltway) westbound (Outer Loop).
Stay to the right to enter I-270 North at the I-270 spur.
Take Exit 1B and turn left at the traffic light at the top of the ramp onto Rockledge Drive.
At the first light, yield to the right to stay on Rockledge Drive.
Rockledge I & II are located on your right.

Parking

At 6701 and 6705 Rockledge Drive parking lots, the building owner has marked designated parking spaces that may include, but are not limited to, TENANT PARKING, VISITOR PARKING, RESERVED PARKING, HANDICAP PARKING, NO PARKING, etc. Any space not otherwise marked is designated for TENANT ONLY PARKING.

Tenant Parking

Tenants must have a valid NIH parking permit issued by ORS displayed in their vehicle at all times in order to park in the parking lots. Parking hangers must be displayed without obstructions. Parking hangers must be hung from the rearview mirror and dash board permits must be placed on the drivers' side dashboard. Vehicles with no permit or failure to display the parking permit properly, may result in the vehicle being towed from the premises.

Visitor/Guest Parking

Visitor/Guest: A person who is NOT a tenant in the building as a permanent duty station.

  • Visitor/Guest parking is only allowed in spaces designated for "VISITOR/GUEST PARKING."
  • Tenants are not eligible for Visitor/Guest Parking.
  • All Visitor/Guest must obtain a valid temporary parking plaque from the guard's desk located in the lobbies of either 6701 and 6705 Rockledge Drive. This plaque must be displayed on the driver's dashboard at all times while vehicle is parked on the premises.

Additional Parking

Additional parking can be found at nearby public parking garages.

  • 6720 Rockledge Drive, Bethesda, MD 20817
  • 6700 Rockledge Drive, Bethesda, MD 20817
  • 6555 Rock Spring Drive, Bethesda, MD 20817

Building Security

At the building entrances where guards are posted:

  • Employees must show a DHHS-issued photo ID (for example, your NIH-issued ID badge).
     
  • Visitors may be required to log in, wear a visitors pass and have an employee escort them through the building.
     
  • Visitors may be required to pass through a metal detector and have bags, backpacks or purses inspected or x-rayed as they enter buildings.
     
  • Security staff will be looking for and confiscating any suspicious or potentially dangerous materials. U.S. Code prohibits bringing any dangerous weapons onto Federal property, including anything with a blade longer than 2 1/2 inches. Meeting participants may want to leave extra bags or personal materials at their hotel to minimize the time needed for inspection.

After-hours building access will require the use of an employee ID on electronic access card readers at building entrances and certain internal areas. 

 

Draft Agenda

7:30am - 8:00am                Registration and Breakfast

8:00am - 8:05am                Welcome and Opening Remarks

o   Sadhana Jackson, MD, Tenure-track Investigator, Head of Developmental Therapeutics, NCI, Pediatric Oncology Branch and NINDS, Surgical Neurology Branch, NIH

o   Maria Castro, PhD, Professor of Neurosurgery and Cell and Developmental Biology, University of Michigan

8:05am - 9:05am                Overview of G34R/V Glioma

o   Epidemiology of Gliomas in AYA population
Quinn Ostrom, PhD, Assistant Professor, Neurosurgery, Population Health Sciences, Duke University, School of Medicine

o   Neuropathology: An Update for the Clinician
Patrick J Cimino, MD, Staff Clinician

Surgical Neurology Branch, NINDS, NIH

o   G34R/V Case Study of Mistaken Identity and Neurodegeneration
Nada Jabado, MD, PhD, Professor of Pediatrics and Human Genetics, McGill University,
Division of Hematology and Oncology at the Montreal Children¿s Hospital

o   Panel Question and Answers
Moderated by Sadhana Jackson, Surgical Neurology Branch, NINDS, NIH

9:05am - 10:40am

Surgical Management and Genomics of G34R/V Diffuse Gliomas

o   Historical lens of Surgery and Perioperative Management Cortical and Diffuse Gliomas
Karin Muraszko, MD, Professor, Neurological Surgery, Pediatrics, Plastic Surgery, University of Michigan

o   Surgical Challenges and Precision Therapy for Cortical Gliomas                       

Chetan Bettagowda, MD, PhD, Professor, Director, Reza Khatib Brain Tumor Center, Johns Hopkins Hospital

o   Methylation of Glioma
Houtan Noushmehr, PhD, Associate Professor of (epi)Genomics and Bioinformatics, Henry Ford Health System

o   Neuro-glial cellular architecture driven by G34R mutation
Mario Suva, MD, PhD, Associate Professor of Pathology, Harvard Medical School and Massachusetts General Hospital, Dana-Farber/Harvard Cancer Center

o   Computational Genomics
Claudia Kleinman, Associate Member, Assistant Professor, McGill Centre for Translational Research in Cancer, Lady Davis Institute for Medical Research, McGill University

o   Panel Question and Answers
Moderated by
Karin Muraszko, MD, Professor, Neurological Surgery, Pediatrics, Plastic Surgery, University of Michigan

 

10:40am - 10:55am Break and Poster Exhibition

10:55am - 12:15pm Translational Research

o   Characterization of the Immune Microenvironment
Maria Castro, PhD, Professor of Neurosurgery and Cell and Developmental Biology, University of Michigan

o   Implementation of Immune mediated Gene therapeutics in H3.3G34R mutated high grade gliomas                                                                 Pedro Lowenstein, Professor of Neurosurgery, Professor, Cell and Developmental Biology, University of Michigan

o   Radiation sensitivity/therapeutic targets
­­Cynthia Hawkins, MD, PhD, FRCPC, Principal Investigator, University of Toronto, The Hospital for Sick Kids

o   Targeted drugs synergize with double alkylator therapy                                                                        Gustavo A.V. Cruzeiro, Postdoctoral Fellow, Dana-Farber Cancer Institute

o   Panel Question and Answers
Moderated by Sadhana Jackson, NINDS/NCI, NIH

12:00am - 1:00pm Lunch and Poster Session

1:00pm ¿ 2:05pm  Small Group Discussions ¿clinicians/scientists mixed in each group

o   Identifying and Addressing Gaps in Diagnosis, Clinical Care and Research (written answers)
Leads: Nellan, Castro, Becher

o   Sharing (presentation of each small group with discussion)

2:05pm - 3:40pm

Management of G34R/V Gliomas: What Trials and Research are on the Horizon?

o   Overview of NCI/NINDS Sponsored Clinical Trials
Sadhana Jackson, MD, Tenure-track Investigator, Head of Developmental Therapeutics, NCI, Pediatric Oncology Branch and NINDS, Surgical Neurology Branch, NIH

o   G34R/V therapeutic targeted clinical trial
Tom Davidson, MD, Associate Professor of Pediatrics, Children¿s Hospital of Los Angeles, Keck School of Medicine of USC

o   Tumor Genomics: What Every Clinician Needs to Know
Adam Resnick, PhD, Co-Director of Data Driven Discovery in Biomedicine and Scientific Chair for Children¿s Brain Tumor Network and Pacific Pediatric Neuro-Oncology Consortium                        

o   Cytokine Reprogramming the Glioma Microenvironment

Delores Hambardzumian, PhD, MBA, Professor of Oncological Sciences and Neurosurgery, Mount Sinai

  • G34R/V modeling and targeted therapy          Adam Green, Associate Professor, Pediatrics-Heme/Onc and Bone Marrow Transplantation, University of Colorado Anschutz School of Medicine

o   Novel BBB therapeutics for brain cancer                  Robert Thorne, PhD, Denali Fellow,                             Denali Therapeutics

o   What can be learned with high throughput drug screening for H3.3 K27?                                              Kelli Wilson, PhD, Acting Director of Compound Management, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH 

o   Panel Question and Answers
Moderated by Maria Castro, University of Michigan

Break | Poster Exhibition-Meet the Experts 

3:40pm -4:00pm

 

4:00pm - 4:50pm

Tumor Board Cases

o   G34R Tumor Board Case: Management recurrent disease | | Case Presenter, Oren Becher, MD

    • Panel

o   Pathologist: Patrick J Cimino

o   Radiation Oncologist: Peter Mathen

o   Neurosurgeon: Karin Muraszko

o   Radiologist: Nadia Biassou, MD

o    G34R Tumor Board Case: Management recurrent disease | | Case Presenter, Brett Theeler, MD 

o   Panel

o   Pathologist: Patrick J Cimino, MD, PhD

o   Radiation Oncologist: Peter Mathen

o   Neurosurgeon: Mark Souweidane

o   Radiologist: Nadia Biassou, MD

o   G34R Tumor Board Case: Management recurrent disease | | Case Presenter, Sheila McThenia, MD

    • Panel

o   Pathologist: Dr. Patrick J Cimino

o   Radiation Oncologist: Peter Mathen

o   Neurosurgeon: Karin Muraszko

o   Radiologist: Nadia Biassou

4:50pm - 5:00pm

Closing Remarks 

Sadhana Jackson, MD and Maria Castro, PhD